Bionexus Gene Lab enters partnership with ML Tech

BioNexus Gene Lab (BGLC) announced a strategic partnership with ML Tech to optimize the BGLC’s Ethereum-based growth strategies. Through this partnership, BGLC plans to leverage ML Tech’s digital asset trading infrastructure to grow its Ethereum holdings. ML Tech, known for its institutional-grade trading strategies and advanced quantitative models, will provide BioNexus with tailored investment solutions designed to maximize returns while maintaining stringent risk management protocols.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on BGLC: